Show simple item record

dc.contributor.authorSchaller, UC
dc.contributor.authorMichl, G
dc.contributor.authorGoebel, FD
dc.contributor.authorKlauss, V
dc.date.accessioned2013-06-18T13:02:47Z
dc.date.available2013-06-18T13:02:47Z
dc.date.issued1999
dc.identifier.citationOphthalmologe. 1999 Apr;96(4):267-9en
dc.identifier.urihttp://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/10409856
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/35691
dc.description.abstractBACKGROUND: Hypopyon-uveitis has been identified as a dosage-dependent side effect in patients with acquired immunodeficiency syndrome who are treated for Mycobacterium avium complex (MAC) infection with systemic rifabutin. PATIENTS AND METHODS: We report a 38-year-old female AIDS patient with bilateral hypopyon uveitis under therapy with rifabutin in combination with clarithromycin and indinavir. RESULTS: At the time of presentation of the bilateral hypopyon uveitis the patient was treated with rifabutin (300 mg/day), clarithromycin (1000 mg/day) and ethambutol (1000 mg/day) for an M. avium complex infection. Also, the patient received the protease inhibitor indinavir. The rifabutin dose was reduced to 150 mg/day. Hypopyon and inflammation resolved under therapy with steroids. CONCLUSIONS: The concomitant use of rifabutin, clarithromycin, and protease inhibitors may lead to hypopyon uveitis. Reduction of dosage of rifabutin (150 mg/day) and treatment with topical steroids are required.en
dc.language.isoenen
dc.title[Acute hypopyon uveitis with rifabutin therapy of systemic Mycobacterium avium complex (MAC) infection in AIDS].en
dc.typeArticleen
local.publisherDepartment of Ophthalmology, College of Health Sciences, University of Nairobien


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record